Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.

The first step to treating hand eczema is to make some lifestyle modifications, but if they don’t work, you might need medical treatment from your primary care doctor or a dermatologist.

is a chronic skin condition that causes small blisters on the palms of the hands, soles of the feet, and the edges of fingers and toes. The blistering rash is itchy and can produce a burning sensation ...

and atopic hand eczema. Diagnosis and assessment can be complex, and management is often challenging. Strategies include structured education, avoidance of trigger factors, primary to tertiary ...

For many people with mild eczema, over-the-counter (OTC) lotions and creams are enough to control eczema symptoms. But if your eczema is severe—or it has stopped responding to OTC strategies—you may ...

LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

LEO Pharma has announced that its Anzupgo (delgocitinib) cream has been approved by the Medicines and Healthcare Products ...

Treating severe eczema can be difficult. However, certain treatment options, such as phototherapy and immunosuppressant drugs, may help manage symptoms. Eczema is a common group of skin conditions ...

dyshidrotic dermatitis Dyshidrotic dermatitis affects fingers, palms of the hands, and soles of the ... can help you identify the correct treatment for eczema. The right treatment for you will ...

Leo Pharma has gained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib) 20mg/g ...